Mitomycin A

CAS : 4055-39-4

Ref. 3D-AM26018

Informations sur le produit

• Nom: Mitomycin A
• Synonymes: (1aS,8S,8aR,8bS)-8-[[(Aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-6,8a-dimethoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indo le-4,7-dione, (1aS,8S,8aR,8bS)-8-[[(Aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-6,8a-dimethoxy-5-methylazirino[2′,3′:3,4]pyrrolo[1,2-a]indole-4,7-dione, 4055-39-4, Azirino[2′,3′:3,4]pyrrolo[1,2-a]indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-6,8a-dimethoxy-5-methyl-, carbamate (ester), Azirino[2′,3′:3,4]pyrrolo[1,2-a]indole-4,7-dione, 8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-6,8a-dimethoxy-5-methyl-, (1aS,8S,8aR,8bS)-, Azirino[2′,3′:3,4]pyrrolo[1,2-a]indole-4,7-dione, 8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-6,8a-dimethoxy-5-methyl-, [1aS-(1aα,8β,8aα,8bα)]-, NSC 75986

Description

Mitomycin A is a cytotoxic antibiotic that has been used in cancer treatment. It is a prodrug that binds to DNA and RNA, inhibiting protein synthesis. Mitomycin A has been shown to be effective in the treatment of bladder cancer, cervical cancer, and some autoimmune diseases. It can be injected or applied topically as an ointment. Mitomycin A is converted by intracellular reduction reactions into its active form, mitomycin C. This drug inhibits the activity of the enzyme RNA polymerase II by binding to the protein-binding site on the enzyme’s alpha subunit, preventing RNA synthesis and cell division. The redox potential of this drug allows it to be activated outside cells and then enter cells where it can bind to nucleic acids and inhibit protein synthesis. Mitomycin A also interacts with proteins involved in DNA repair, such as Rad51, which may account for its effectiveness against cervical cancer cells that are deficient in homologous recomb

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 349.34 g/mol
• Formule: C₁₆H₁₉N₃O₆
• Degré de pureté: Min. 95%
• Couleur/Forme: Purple Powder